{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:22:41Z","timestamp":1790799761886,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1053\/j.semnuclmed.2015.12.005","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T23:04:48Z","timestamp":1460156688000},"page":"250-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Targeted Radionuclide Therapy of Melanoma"],"prefix":"10.1053","volume":"46","author":[{"given":"Abdullah","family":"Norain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Dadachova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2015.12.005_bib1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/jid.2008.423","article-title":"Increasing burden of melanoma in the United States","volume":"129","author":"Linos","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2015.12.005_bib2","article-title":"BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma","volume":"29","author":"Ribas","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2015.12.005_bib3","article-title":"Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma","volume":"29","author":"Chapman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2015.12.005_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma,","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2015.12.005_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/intimm\/dxu095","article-title":"Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies","volume":"27","author":"Philips","year":"2015","journal-title":"Int Immunol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib6","first-page":"434","article-title":"Radioimmunotherapy for melanoma","volume":"29","author":"DeNardo","year":"1981","journal-title":"Clin Res"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1148\/radiology.155.2.3983400","article-title":"Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: Preliminary experience","volume":"155","author":"Larson","year":"1985","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semnuclmed.2005.02.006","article-title":"Treatment of non-Hodgkin\u2019s lymphoma (NHL) with radiolabeled antibodies (mAbs)","volume":"35","author":"DeNardo","year":"2005","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib10","series-title":"Rational Basis for Chemotherapy","article-title":"The evaluation of radiolabeled monoclonal antibody parameters necessary for cancer immunotherapy","author":"DeNardo","year":"1983"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib11","series-title":"Radioimmunoimaging and Radioimmunotherapy","article-title":"Monoclonal antibody radiopharmaceuticals for cancer radioimmunotherapy","author":"DeNardo","year":"1983"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib12","first-page":"220","article-title":"Radioimmunodetection of malignant melanoma with the 225.28S monoclonal antibody to HMW-MAA","volume":"25","author":"Buraggi","year":"1986","journal-title":"Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib13","first-page":"761","article-title":"A 94,000-Dalton glycoprotein expressed by human melanoma and carcinoma cells","volume":"68","author":"Imai","year":"1982","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4049\/jimmunol.127.2.539","article-title":"Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies","volume":"127","author":"Brown","year":"1981","journal-title":"J Immunol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib15","first-page":"5","article-title":"New techniques for imaging metastatic melanoma","volume":"16","author":"Kang","year":"1998","journal-title":"Surgery"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02841868609136368","article-title":"Radiation biology of malignant melanoma","volume":"25","author":"Rofstad","year":"1986","journal-title":"Acta Radiol Oncol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/0008-5472.CAN-03-2658","article-title":"Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: Radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor","volume":"64","author":"Rofstad","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib18","first-page":"329","article-title":"Radioimmunodetection of human melanoma with indium-111-labeled monoclonal antibody","volume":"29","author":"Taylor","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1053-4296(00)80051-X","article-title":"Radioimmunotherapy: Designer molecules to potentiate effective therapy","volume":"10","author":"Milenic","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib20","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrd1413","article-title":"Antibody-targeted radiation cancer therapy","volume":"3","author":"Milenic","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2015.12.005_bib21","first-page":"115S","article-title":"Perspectives on cancer therapy with radiolabeled monoclonal antibodies","volume":"46","author":"Sharkey","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1053-4296(00)80050-8","article-title":"Review of low-dose-rate radiobiology for clinicians","volume":"10","author":"Murtha","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-8140(92)90342-R","article-title":"Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam radiation","volume":"23","author":"Knox","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib24","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1073\/pnas.182209699","article-title":"Bystander effect produced by radiolabeled tumor cells in vivo","volume":"99","author":"Xue","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ijrobp.2004.04.008","article-title":"How and why does radioimmunotherapy work?","volume":"59","author":"Macklis","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib26","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1200\/JCO.2001.19.19.3976","article-title":"Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial","volume":"19","author":"Scott","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00259-006-0124-4","article-title":"Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT)","volume":"34","author":"Urbano","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib28","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1039\/b704726f","article-title":"Targeted alpha-therapy: Past, present, future?","author":"Brechbiel","year":"2007","journal-title":"Dalton Trans"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib29","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4161\/cbt.4.12.2251","article-title":"Intralesional targeted alpha therapy for metastatic melanoma","volume":"4","author":"Allen","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10.1053\/j.semnuclmed.2015.12.005_bib30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.6.6.4089","article-title":"Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma","volume":"6","author":"Raja","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/cbr.2008.0493","article-title":"Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmuno-diagnostic and radioimmunotherapeutic applications","volume":"23","author":"Milenic","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib32","doi-asserted-by":"crossref","first-page":"14865","DOI":"10.1073\/pnas.0406180101","article-title":"Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin","volume":"101","author":"Dadachova","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib33","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1128\/IAI.68.5.2845-2853.2000","article-title":"Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents","volume":"68","author":"Rosas","year":"2000","journal-title":"Infect Immun"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0749.2002.02017.x","article-title":"Advanced chemical methods in melanin determination","volume":"15","author":"Wakamatsu","year":"2002","journal-title":"Pigment Cell Res"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib35","first-page":"390","article-title":"Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA","volume":"30","author":"Matzku","year":"1989","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/CMR.0b013e3282eeeae7","article-title":"Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to the metastatic melanoma tumors with wide range of melanin concentrations","volume":"17","author":"Schweitzer","year":"2007","journal-title":"Melanoma Res"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib37","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4161\/cbt.7.7.6197","article-title":"Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with (188)Re against experimental human metastatic melanoma in nude mice","volume":"7","author":"Dadachova","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2015.12.005_bib38","first-page":"52","article-title":"Imaging of metastatic melanoma (MM) with a 188Rhenium(188Re)-labeled melanin binding antibody","volume":"49","author":"Klein","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/828329","article-title":"Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma","volume":"2013","author":"Klein","year":"2013","journal-title":"J Skin Cancer"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib40","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1158\/1078-0432.CCR-08-2376","article-title":"Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine","volume":"15","author":"Revskaya","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2015.12.005_bib41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/imt.13.16","article-title":"Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma","volume":"5","author":"Jandl","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc receptors","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu Review Immunol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib43","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1200\/JCO.2007.15.5465","article-title":"Melanoma stem cells: The dark seed of melanoma","volume":"26","author":"Zabierowski","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2015.12.005_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.nucmedbio.2012.10.006","article-title":"Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy","volume":"40","author":"Jandl","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1196\/annals.1294.026","article-title":"Peptide receptor radionuclide therapy","volume":"1014","author":"Krenning","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s002590050488","article-title":"Peptide radiopharmaceuticals in nuclear medicine","volume":"26","author":"Blok","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/bc034069i","article-title":"Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues","volume":"4","author":"Miao","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib48","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/0008-5472.CAN-03-0193","article-title":"Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma","volume":"64","author":"Cheng","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib49","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1158\/1078-0432.CCR-05-0619","article-title":"Melanoma therapy via peptide-targeted alpha-radiation","volume":"11","author":"Miao","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/cbr.2007.376.A","article-title":"Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model","volume":"22","author":"Miao","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib51","first-page":"121","article-title":"Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models","volume":"46","author":"Miao","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/MCB.19.1.745","article-title":"Melanization of Cryptococcus neoformans in murine infection","volume":"19","author":"Nosanchuk","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/cbr.2006.21.117","article-title":"Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease","volume":"21","author":"Dadachova","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib54","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s003359900551","article-title":"Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment","volume":"8","author":"Rogers","year":"1997","journal-title":"Mamm Genome"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib55","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/bc060330u","article-title":"Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma","volume":"18","author":"Howell","year":"2007","journal-title":"Bioconjugate Chem"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib56","first-page":"1260","article-title":"Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide)","volume":"34","author":"Michelot","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib57","first-page":"1865","article-title":"Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma","volume":"37","author":"Brandau","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib58","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00259-002-0971-6","article-title":"123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging","volume":"29","author":"Moins","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib59","first-page":"9","article-title":"Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52","volume":"55","author":"Mier","year":"2014","journal-title":"J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2015.12.005_bib60","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1158\/0008-5472.CAN-09-4414","article-title":"Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma","volume":"70","author":"Joyal","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2015.12.005_bib61","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/14796694.1.4.541","article-title":"Melanin as a potential target for radionuclide therapy of metastatic melanoma","volume":"1","author":"Dadachova","year":"2005","journal-title":"Future Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299815001543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299815001543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T12:04:12Z","timestamp":1718453052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299815001543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0001299815001543"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.12.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Radionuclide Therapy of Melanoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}